Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 18/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105543 | 0.89 | CYP17A1 (0.48) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL359295 | 0.88 | CYP17A1 (0.63) | CYP17A1CYP1A2CYP3A4CYP11B1LMNA | |
| SCHEMBL15113035 | 0.86 | CYP17A1 (0.56) | CYP17A1CYP1A2LMNA | |
| SCHEMBL10188375 | 0.84 | CYP17A1 (0.62) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL10187424 | 0.84 | CYP17A1 (0.56) | CYP17A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL25342346 | 0.83 | CYP17A1 (0.60) | CYP17A1CYP1A2SCN9ACYP3A4CYP11B1 | |
| SCHEMBL25975112 | 0.83 | CYP17A1 (0.74) | CYP17A1CYP1A2SCN9A | |
| SCHEMBL368199 | 0.80 | CYP17A1 (0.60) | CYP17A1CYP1A2SCN9A | |
| SCHEMBL368959 | 0.80 | CYP17A1 (0.58) | CYP17A1CYP1A2CYP3A4CYP11B1LMNA | |
| SCHEMBL10187423 | 0.77 | CYP17A1 (0.43) | CYP17A1CYP1A2CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | CYP3A7, CYP2C19, UGT2B17 | CYP17A1 45/4885CYP1A2 8/4885SCN9A 2334/4885 |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | CYP17A1 53/4885CYP1A2 9/4885SCN9A 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.